New and Emerging Aldosterone Agonists

The Latest Aldosterone Agonists:

The field of aldosterone-targeting therapies has experienced remarkable advancement in recent years, with several novel compounds emerging as the "latest" aldosterone agonists - though it's important to clarify that these are actually aldosterone antagonists rather than agonists. The most recent breakthrough medications work by either blocking aldosterone receptors or inhibiting aldosterone synthesis, representing significant improvements over older medications like spironolactone.

Lorundrostat: The Latest FDA Success Story

Lorundrostat represents the most recent major breakthrough in aldosterone-targeted therapy, having successfully completed its pivotal Phase 3 Launch-HTN trial in 2025. This aldosterone synthase inhibitor works by directly reducing aldosterone production through selective inhibition of the CYP11B2 enzyme.primaryaldosteronism+3

The Launch-HTN trial, involving over 1,083 participants with uncontrolled or treatment-resistant hypertension, demonstrated that lorundrostat significantly reduced systolic blood pressure by approximately 8 mmHg compared to placebo when measured over 24 hours. Remarkably, lorundrostat 50 mg once daily achieved clinical blood pressure reductions of 16.9 mmHg at Week 6 and 19.0 mmHg at Week 12. The medication was generally well-tolerated, with treatment-emergent adverse events being mostly mild and transient.pubmed.ncbi.nlm.nih+2

Next-Generation Non-Steroidal Mineralocorticoid Receptor Antagonists

Finerenone (Kerendia): The Current Gold Standard

Finerenone holds the distinction of being the most recently approved aldosterone antagonist for clinical use, having received FDA approval on July 9, 2021. This non-steroidal mineralocorticoid receptor antagonist represents a significant advancement over older steroidal compounds like spironolactone and eplerenone.pmc.ncbi.nlm.nih+2

In July 2025, finerenone received expanded FDA approval for treating patients with heart failure and left ventricular ejection fraction ≥40%. This approval was based on the successful FINEARTS-HF trial, which demonstrated a 16% relative risk reduction in the composite primary endpoint of cardiovascular death and total heart failure events.dicardiology+1

Finerenone's unique molecular structure provides several advantages over traditional mineralocorticoid receptor antagonists:pmc.ncbi.nlm.nih+1

• Higher selectivity for mineralocorticoid receptors (at least 500-fold compared to other steroid hormone receptors)
• Balanced tissue distribution in both kidney and cardiac tissue
• Reduced risk of hyperkalemia compared to spironolactone
• Superior cardiovascular and renal protective effects

Esaxerenone: The Japanese Innovation

Esaxerenone (CS-3150) received its first global approval in Japan in January 2019 for treating hypertension. This non-steroidal mineralocorticoid receptor antagonist demonstrates remarkable potency, with at least 1,000 times higher selectivity for mineralocorticoid receptors compared to other antagonists.nature+2

Clinical trials have shown esaxerenone to be highly effective:

• ESAX-HTN study: Esaxerenone 5 mg daily showed superior antihypertensive activity to eplerenone 50 mg dailyacademic.oup+1
• ESAX-DN trial: Demonstrated efficacy in reducing urinary albumin-to-creatinine ratio in patients with type 2 diabetes and microalbuminuriapmc.ncbi.nlm.nih

The medication exhibits excellent tolerability, with no agonistic or antagonistic effects on glucocorticoid, progesterone, or androgen receptors.nature

Aldosterone Synthase Inhibitors: The Revolutionary Approach

Beyond lorundrostat, several other aldosterone synthase inhibitors are advancing through clinical development, representing an entirely new therapeutic approach.pubmed.ncbi.nlm.nih+1

Baxdrostat: The Promising Contender

Baxdrostat (CIN-107) has shown exceptional promise in Phase 2 trials for treatment-resistant hypertension. The BrigHTN trial demonstrated that baxdrostat:pmc.ncbi.nlm.nih+1

• Reduced systolic blood pressure by 8.1-11.0 mmHg (depending on dose) compared to placeboacademic.oup
• Decreased urinary aldosterone by 51-73% across dosespmc.ncbi.nlm.nih
• Showed excellent selectivity (100:1 ratio) for aldosterone synthase over cortisol synthesispmc.ncbi.nlm.nih

Baxdrostat is currently advancing into Phase 3 trials and represents a potential game-changer for resistant hypertension management.clinicaltrials+1

Other Emerging Aldosterone Synthase Inhibitors

The pipeline includes several other promising compounds:primaryaldosteronism

• Dexfadrostat: Completed Phase 2 studies showing decreased aldosterone-to-renin ratio and systolic pressure
• JX09 (formerly PB6440): A highly selective inhibitor with minimal impact on cortisol synthesis, currently in Phase 1 development

Compounds with Mixed Development Status

Ocedurenone: The Discontinued Promise

Ocedurenone (KBP-5074) was a third-generation non-steroidal mineralocorticoid receptor antagonist that showed initial promise in the BLOCK-CKD Phase 2b trial for patients with advanced chronic kidney disease and resistant hypertension. However, the Phase 3 CLARION-CKD trial failed to meet its primary endpoint, leading to discontinuation of development.biospace+3

Balcinrenone: The Ongoing Investigation

Balcinrenone (AZD9977) remains under investigation by AstraZeneca, despite earlier setbacks. The MIRACLE trial showed no significant reduction in urinary albumin-to-creatinine ratio when combined with dapagliflozin compared to dapagliflozin alone. However, the compound continues to be studied for heart failure and chronic kidney disease applications.academic.oup+3

Clinical Significance and Future Outlook

The emergence of these latest aldosterone-targeting therapies addresses critical limitations of traditional medications:

Traditional Limitations Addressed:

• Hyperkalemia risk: New compounds show reduced potassium elevation
• Sexual side effects: Non-steroidal compounds avoid gynecomastia and impotence
• Limited efficacy: Newer agents show superior cardiovascular and renal protection

Future Development Priorities:pubmed.ncbi.nlm.nih+1

• Combination therapies: Integration with SGLT2 inhibitors and other cardiovascular medications
• Precision medicine: Tailoring therapy based on individual aldosterone profiles
• Expanded indications: Beyond hypertension to include heart failure, chronic kidney disease, and primary aldosteronism

Conclusion

The "latest" aldosterone antagonists represent a paradigm shift in cardiovascular and renal medicine. Lorundrostat stands out as the most recent success story with completed Phase 3 trials, while finerenone remains the current clinical gold standard with the most extensive regulatory approvals. Esaxerenone offers regional success in Japan, and the aldosterone synthase inhibitor class, led by baxdrostat, promises to revolutionize treatment approaches.

These advances provide clinicians with more effective, better-tolerated options for managing hypertension, heart failure, and chronic kidney disease, particularly in patients who cannot tolerate traditional mineralocorticoid receptor antagonists. The next few years will likely see several of these compounds receive broader regulatory approval, fundamentally changing how we approach aldosterone-mediated cardiovascular and renal diseases.

1. https://primaryaldosteronism.org/next-generation-pa-drugs/
2. https://www.qmul.ac.uk/media/news/2025/medicine-and-dentistry/fmd/new-drug-tackles-uncontrolled-hypertension-caused-by-aldosterone-dysregulation.html
3. https://pubmed.ncbi.nlm.nih.gov/40587141/
4. https://ir.mineralystx.com/news-events/press-releases/detail/74/mineralys-therapeutics-announces-journal-of-the-american
5. https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2025/03/27/15/49/advance-htn
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC11649598/
7. https://www.drugs.com/history/kerendia.html
8. http://bayer2019tf.q4web.com/news/news-details/2021/Bayers-KERENDIA-finerenone-Receives-U.S.-FDA-Approval-for-Treatment-of-Patients-with-Chronic-Kidney-Disease-Associated-with-Type-2-Diabetes/default.aspx
9. https://www.dicardiology.com/content/fda-approves-kerendia-patients-heart-failure-left-ventricular-ejection-fraction
10. https://www.tctmd.com/news/fda-approves-finerenone-hf-patients-mildly-reduced-or-preserved-ef
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC9900468/
12. https://www.nature.com/articles/s41371-019-0207-x
13. https://www.nature.com/articles/s41371-023-00889-9
14. https://europepmc.org/article/med/30806972
15. https://academic.oup.com/eurheartj/article/46/27/2618/8111531
16. https://pubmed.ncbi.nlm.nih.gov/39656736/
17. https://pmc.ncbi.nlm.nih.gov/articles/PMC10348457/
18. https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2022.1097968/full
19. https://clinicaltrials.gov/study/NCT06034743?cond=%28CORTICOSTERONE+METHYLOXIDASE+TYPE+I+DEFICIENCY%29+OR+%28CYP11B2%29&rank=6
20. https://www.astrazenecaclinicaltrials.com/study/D6973C00001
21. https://www.biospace.com/ocedurenone-kbp-5074-featured-at-asn-kidney-week-ocedurenone-is-a-potential-new-treatment-option-for-patients-with-uncontrolled-or-resistant-hypertension-and-advanced-ckd
22. https://trial.medpath.com/drug/d3bd1bcae7f4b921/ocedurenone
23. https://link.springer.com/article/10.1007/s13318-023-00837-5
24. https://synapse.patsnap.com/drug/23212eeb60db49f588969dbb88e47686
25. https://academic.oup.com/ckj/article/18/1/sfae346/7906595
26. https://adisinsight.springer.com/drugs/800042795
27. https://pmc.ncbi.nlm.nih.gov/articles/PMC11812937/
28. https://www.astrazenecaclinicaltrials.com/study/D6402C00001/
29. https://pmc.ncbi.nlm.nih.gov/articles/PMC8099290/
30. https://pmc.ncbi.nlm.nih.gov/articles/PMC1200656/
31. https://www.cfrjournal.com/articles/evidence-aldosterone-antagonism-heart-failure?language_content_entity=en
32. https://www.sciencedirect.com/science/article/pii/S0211699524000985
33. https://my.clevelandclinic.org/health/treatments/22917-aldosterone-antagonists
34. https://www.nature.com/articles/s41440-024-01809-1
35. https://www.jacc.org/doi/10.1016/j.jacadv.2025.101762
36. https://www.sciencedirect.com/science/article/pii/S0167527301005162
37. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.896947/full
38. https://pubmed.ncbi.nlm.nih.gov/39613858/
39. https://www.heartfailurematters.org/what-your-doctor-can-do/aldosterone-receptor-antagonists-or-mineralocorticoid-receptor-antagonist-mras/
40. https://academic.oup.com/eurheartj/article/42/2/152/5936792
41. https://www.sciencedirect.com/science/article/abs/pii/S1071916425002039
42. https://en.wikipedia.org/wiki/Mineralocorticoid_receptor_antagonist
43. https://consultqd.clevelandclinic.org/lorundrostat-shows-continued-promise-against-uncontrolled-hypertension
44. https://www.nature.com/articles/s41440-022-01070-4
45. https://pubmed.ncbi.nlm.nih.gov/40651462/
46. https://pubmed.ncbi.nlm.nih.gov/36342143/
47. https://www.withpower.com/trial/phase-3-renal-insufficiency-chronic-10-2021-9375d
48. https://www.sciencedirect.com/science/article/abs/pii/S0146280623003353
49. https://ysioscapital.com/2025/05/26/mineralys-therapeutics-announces-late-breaking-presentation-of-data-from-the-launch-htn-pivotal-trial-of-lorundrostat-in-uncontrolled-or-resistant-hypertension-at-34th-european-meeting-on-hypertension/
50. https://pubmed.ncbi.nlm.nih.gov/31113987/
51. https://www.ahajournals.org/doi/pdf/10.1161/HYPERTENSIONAHA.119.13569
52. https://www.hcplive.com/view/fda-accepts-finerenone-snda-for-heart-failure-grants-priority-review
53. https://clinicaltrials.gov/study/NCT04595370
54. https://www.medchemexpress.com/balcinrenone.html
55. https://pubmed.ncbi.nlm.nih.gov/31786983/
56. https://pubmed.ncbi.nlm.nih.gov/34519996/
57. https://discover.lshtm.ac.uk/discovery/fulldisplay?docid=cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6682830&context=PC&vid=44HYG_INST%3A44HYG_VU1&lang=en&search_scope=MyInst_and_CI&adaptor=Primo+Central&tab=Everything&query=sub%2Cexact%2C+Sulfones+-+administration+%26+dosage+%2CAND&mode=advanced&offset=0
58. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215341s000lbl.pdf
59. https://www.sciencedirect.com/science/article/abs/pii/S0090955624078607